• 
  A Brief Overview of Emerging Target: STEAP Xiaobin
  July 11, 2025
  As the "low-hanging fruit" in drug discovery becomes increasingly scarce, pharmaceutical companies are shifting their focus toward novel targets. At this year's AACR Annual Meeting, AstraZeneca unveiled preclinical data for AZD0516, a drug candidate targe
• 
  2025 Q1: Oncology Business Competition Among MNCs Xiaobin
  June 04, 2025
  How did MNCs fare in the oncology field during Q1 of this year?
• 
  Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
  April 28, 2025
  This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.

• 
  Pharma Sources Insight July 2025: GLOBAL API SOURCING TRENDS Pharma Sources Insight
  July 11, 2025
  Pharma Sources Insight July 2025 focuses on global API sourcing trends and more.

• 
  Alzheimer’s Disease: Charting the Course from Plaques to Promise Muhammad Farhan Khalid
  May 28, 2025
• 
  CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets ACN Newswire
  July 21, 2025
• 
  InnoCare Announces FDA Approval of Clinical Trial for BCL2 Inhibitor Mesutoclax in AML and MDS PharmaSources
  July 14, 2025
  July 14, 2025 ，InnoCare Pharma announced that FDA has approved the Investigational New Drug application to conduct the clinical trial of BCL2 inhibitor mesutoclax in combination with azacitidine for the treatment of myeloid malignancies.

• 
  Popular Products and Companies at PharmaSources.com (January 2025) PSI
  January 15, 2025
  Popular Products and Companies at PharmaSources.com
• 
  Research and Application of Artemisia Argyi Xiaonisha
  August 12, 2024
• 
  Research Progress on the Anti-HBV Effects of Natural Compounds Xiaomichong
  July 23, 2024

• 
  Apeloa Pharmaceutical releases first ESG PharmaSources
  May 12, 2025
  Apeloa Pharmaceutical has released its first sustainability report. Apeloa’s 2024 Environmental, Social and Governance (ESG) report marks the start of continuous and responsible disclosure into the future.